Immune checkpoint inhibitors (ICIs) represent one of the main steps forward for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC), without oncogenic driver alterations. Despite this recent progress, only a minority of patients achieve a broad and durable benefit and another proportion report poor survival and sometimes fast disease progression, confirming the need to optimise the patient's selection. To date, several issues are unsolved about how to personalise the immunotherapy treatment for individual patients. In this review, analysing data from pivotal randomised clinical trials (RCTs), we discuss patient baseline clinical and demographic features, including sex, age, ECOG performance status, smoking habit and specific site of metastases (liver, bone and brain) that may influence the efficacy outcomes in patients treated with ICIs. The high performance of the ICIs blurred the vision on different efficacy-limiting factors, which require extensive evaluation to improve the understanding of the tumour-specific immune response, in which clinical drivers could be useful for better patient stratification.

Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: a critical review of published data / Passaro, Antonio; Attili, Ilaria; Morganti, Stefania; Del Signore, Ester; Gianoncelli, Letizia; Spitaleri, Gianluca; Stati, Valeria; Catania, Chiara; Curigliano, Giuseppe; de Marinis, Filippo. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 89:(2020), pp. 1-10. [10.1016/j.ctrv.2020.102085]

Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: a critical review of published data

Stati Valeria;
2020

Abstract

Immune checkpoint inhibitors (ICIs) represent one of the main steps forward for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC), without oncogenic driver alterations. Despite this recent progress, only a minority of patients achieve a broad and durable benefit and another proportion report poor survival and sometimes fast disease progression, confirming the need to optimise the patient's selection. To date, several issues are unsolved about how to personalise the immunotherapy treatment for individual patients. In this review, analysing data from pivotal randomised clinical trials (RCTs), we discuss patient baseline clinical and demographic features, including sex, age, ECOG performance status, smoking habit and specific site of metastases (liver, bone and brain) that may influence the efficacy outcomes in patients treated with ICIs. The high performance of the ICIs blurred the vision on different efficacy-limiting factors, which require extensive evaluation to improve the understanding of the tumour-specific immune response, in which clinical drivers could be useful for better patient stratification.
2020
antineoplastic agents; immunological; antineoplastic combined chemotherapy protocols; B7-H1 antigen; carcinoma; non-small-cell lung; clinical trials, phase II as topic; clinical trials, phase III as topic; humans; lung neoplasms; programmed cell death 1 receptor; randomized controlled trials as topic
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: a critical review of published data / Passaro, Antonio; Attili, Ilaria; Morganti, Stefania; Del Signore, Ester; Gianoncelli, Letizia; Spitaleri, Gianluca; Stati, Valeria; Catania, Chiara; Curigliano, Giuseppe; de Marinis, Filippo. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 89:(2020), pp. 1-10. [10.1016/j.ctrv.2020.102085]
File allegati a questo prodotto
File Dimensione Formato  
Passaro_Clinical_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 590.13 kB
Formato Adobe PDF
590.13 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1485696
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 37
social impact